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Objective: The aim of this study was the molecular characterization of the AR gene as the cause of 46,XY disorder in our population.
Methods: We studied 41, non related, 46,XY disorder of sexual differentiation index cases, having characteristics consistent with androgen 
insensivity syndrome (AIS). Genomic DNA was isolated from peripheral blood leukocytes of all patients and 25 family members from 
17 non-related families.
Results: The AR gene analysis revealed an abnormal sequence in 58.5% of the index patients. All of the complete AIS (CAIS) cases were 
genetically confirmed, while in the partial form (PAIS) a mutation in AR was detected in only 13 (43.3%). Molecular studies revealed 
other affected or carrier relatives in 87% of the index cases. The AR mutations were found spread along the whole coding sequence, 
with a higher prevalence in the ligand binding domain. Nine out of 23 (39%) AR mutations were novel. In 17% of patients with detected 
AR mutations, somatic mosaicism was detected in leucocyte DNA. In our cohort, long-term follow up gender dysphoria, raised as male 
or female, was not found. Finally, in suspected PAIS, the identification of AR mutation occurred significantly less than in CAIS patients.
Conclusion: Improved knowledge of the components of the AR complex and signaling network might contribute to long term outcome 
and genetic counseling in AIS patients.
Keywords: 46,XY disorders of sex development, androgen insensitivity syndrome, androgen receptor gene mutations, mosaicism, 
clinical phenotype
Introduction
The endogenous androgens, testosterone (T) and 
dihydrotestosterone (DHT), exert their effects via a single 
intracellular receptor protein, the androgen receptor (AR) 
(1). AR-mediated androgen action is essential for normal 
primary male sexual development before birth and for 
normal secondary male sexual development around 
puberty, whereas in females, androgens also participate 
in sexual development around puberty and in adult 
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What is already known on this topic?
What this study adds?
Androgen insensitivity syndromes (AIS) the most frequent known monogenic cause of 46,XY disorder of sexual differentiation. Mutations 
of variable severity in androgen receptor gene are associated with a wide phenotypic spectrum, ranging from complete AIS to a partial 
form or a mild form.
Characterization of the clinical phenotype, long term follow up, in particular gender identityand the contribution of the AR gene to the 
molecular cause of 46,XY disorder of sexual differentiation in a single tertiary pediatric center of Buenos Aires, Argentina are reported. 
Nine novel AR mutations are described
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female sexual function (2). The AR gene is located on 
the X-chromosome inthe Xq11–12 region and encodes a 
protein with a molecular mass of approximately 110 kDa. 
The gene consists of eight coding exons (I to VIII) (3). The 
AR is a transcription factor that belongs to the nuclear 
receptor subfamily 3, group C, member 4. The protein 
consists of 920 amino acids that, like other nuclear 
receptors, is composed of an N-terminal domain (NTD), 
located on exon 1, a DNA-binding domain (DBD), located 
on exons 2 and 3 containing two zinc fingers, a hinge 
region connecting the ligand-binding domain (LBD) to the 
DBD and a C-terminal LBD, located on exons 4-8 (4). 
Androgen insensitivity syndrome (AIS; OMIM 300068) 
is the most frequent known monogenic cause of 46,XY 
disorders of sex development (DSD) and is an X-linked 
recessive condition. Mutations of variable severity in 
the AR gene are associated with a wide phenotypic 
spectrum, ranging from complete AIS (CAIS) to a partial 
form (PAIS) or a mild form (MAIS). Patients who present 
with CAIS exhibit female external genitalia, testes located 
in the inguinal or abdominal area, and complete breast 
development with sparse to absent axillary and pubic 
hair. Patients with PAIS present with a predominantly 
male phenotype with hypospadias or a predominantly 
female phenotype with cliteromegaly and/or posterior 
labial fusion, ambiguous genitalia and variable degrees of 
gynecomastia at puberty. Patients with MAIS present with 
normal external male genitalia associated with infertility 
(5).
The aim of this study was to characterize the clinical 
phenotype and the contribution of the AR gene to the 
molecular cause of 46,XY DSD in our population.
Methods
We studied 41 unrelated 46,XY DSD patients with clinical 
and hormonal characteristics consistent with AIS. CAIS was 
suspected in 11 of the patients and PAIS in 30. All patients 
presented with female or ambiguous external genitalia, 
adequate T production without evidence of steroidogenic 
blockade and no Müllerian structures evident on abdominal 
ultrasound. Patients with hormonal determinations 
previous to gonadal biopsy or gonadectomy presented 
no biochemical evidence of gonadal dysgenesis and had 
normal male follicle-stimulating hormone (FSH) levels. In 
these individuals, the AR gene was the first candidate for 
molecular analysis.
Informed consent for the genetic study was obtained 
from all of the patients or their parents guardians after full 
explanation of the purpose and nature of all procedures.
The study was approved by the Independent Ethics 
Committee “Prof. Dr. J. P. Garrahan Pediatric Hospital” 
(reference number: 971). 
Hormonal Assays
Serum luteinising hormone (LH) and FSH levels were 
determined by the IMX systems (Abbott Laboratories, 
Abbott Park, IL); assay sensitivity was 0.3 IU/L for LH and 
0.2 IU/L for FSH; interassay coefficient of variation ranged 
from 3.1-8.7% for LH and from 3.8-12% for FSH. Serum 
anti-Müllerian hormone (AMH) levels were determined by 
ELISA; assay sensitivity was 0.5 pmol/L and assay limit 
of quantification 1.2 pmol/L serum T was determined by 
a DPC Immulite® Assay System (Diagnostic Products, Los 
Angeles, CA); assay sensitivity was 0.17 nmol/L; interassay 
coefficient of variation ranged from 7.4 to 13%.
AR Gene Mutation Analysis
Genomic DNA was isolated from peripheral blood leukocytes 
of all patients (41 index cases) and 25 family members from 
17 families according to standard procedures. There were 
seven families in which family members were not available 
for molecular studies. The entire coding region (exons 1-8) 
and splice sites in flanking intronic regions of AR gene were 
polymerase chain reaction (PCR) amplified and sequenced 
by automated analysers (6).
After PCR, the products were assessed by electrophoresis 
on a 1% agarose gel stained with ethidium bromide and 
showed a single band with expected size. The PCR products 
were purified (Qia Quick PCR Purification Kit, Qiagen, 
Buenos Aires, Argentina) and sequenced using a BigDye 
Terminator version 3.1 cycle sequencing kit (Applied 
Biosystems, Buenos Aires, Argentina) on an ABI PRISM® 
3130 Genetic Analyzer capillary DNA sequencer (Applied 
Biosystems, Buenos Aires, Argentina). The primers used for 
sequencing were the same as those used for PCR. Previously 
reported intronic mutations were also analysed [Human 
Gene Mutation Database (HGMD), www.hgmd.cf.ac.uk/]. 
The nucleotide sequences obtained were compared with 
those from Genebank accession number: NG_009014.2. 
Nucleotide changes were reconfirmed in each sample DNA 
by antisense sequence and resequencing after a new PCR 
product was produced from the original DNA extract.
In silico Protein Analysis
Nonsense and frameshift mutations which implicate 
a premature stop codon and a truncated protein were 
considered deleterious.
The sequence homology-based tool, [Sorting Intolerant 
from Tolerant (SIFT); http://sift.jcvi.org/], version 2.0.6, 
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the structure-based tool PolyPhen-2 (Polymorphism 
Phenotyping v2, http://genetics.bwh.harvard.edu/pph2/) 
and Mutation Taster (http://www.mutationtaster.org/) 
were used to predict the pathogenicity of the previously 
undescribed missense variants using default settings. To 
evaluate the implication of a novel synonymous mutation, 
we used The Berkeley Drosophila Genome Project (http://
www.fruitfly.org/) as a splice site prediction program.
The SIFT algorithm predicts the functional importance of the 
substitutions based on the alignment of orthologous and/or 
paralogous protein sequences. The PolyPhen-2 algorithm 
predicts the functional effects of amino acid changes by 
considering conservation, physicochemical differences 
and the proximity of the substitution to the predicted 
functional domains. Unlike SIFT or PolyPhen which handle 
only single amino acid substitutions, MutationTaster works 
on the DNA level and allows insertions and deletions up to 
12 base pairs.
The original sequence of the protein was obtained from the 
Ensembl and UniProt/Swiss-Prot databases.
Statistical Analysis
This study describes the genotype and clinical phenotype of 
patients with AIS. A statistical analysis was not necessary. 
Results
In our study AR gene analysis revealed an abnormal 
sequence in 24 individuals (58.5% of total index patients). 
All of the CAIS cases (n=11) were genetically confirmed, 
while in PAIS (n=30) a mutation in AR was detected in only 
13 patients (43.3%).
Family studies were performed in 25 family members from 
17 families. The molecular studies and affected family 
members are shown in Table 1. Molecular studies revealed 
other affected or carrier relatives in 87% of the index cases. 
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Table 1. Clinical phenotype, social sex and molecular studies
Patient Clinical form Social sex Mutation
Location





















































De novo AR mutations were found in three (P3, P5 and 
P6) out of 13 mothers analyzed. In two non-related index 
cases (P12 A and P15), two 46,XY affected siblings raised 
as female were detected. Interestingly, even though in P12A 
PAIS was established, normal external female genitalia, 
in the affected sister, was observed (P12 B). As shown in 
Table 1, 23 AR mutations were detected. The AR mutations 
were found spread along the whole coding sequence, with 
a higher prevalence in LBD: 8.3% were located in NTD; 
16.6% in the DBD; 70.8% in the LBD and 4.3% were gross 
deletions (7). 
Nine out of 23 (39%; P1, P6, P8, P13, P15, P16, P22, P23 
and P24) AR mutations were novel. Two novel mutations 
were located in the NTD domain (P1 and P16). They 
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Table 1. Continued
Patient Clinical form Social sex Mutation
Location






































































LBD 8 Hereditary Mother carrier
anovel mutation. CAIS: complete androgen insensitivity syndrome, PAIS: partial androgen insensitivity syndrome, F: female, M: male, NTD: N-terminal domain, 
DBD: DNA-binding domain, LBD: ligand-binding domain, AIS: androgen insensitivity syndromes
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were both out of frame deletions that ultimately created 
a nonsense stop codon and premature truncation of the 
protein. The others, located in the LBD, were:four missense 
mutations, a nonsense mutation together with a 2bp 
deletion and a duplication of 7bp that produce a frameshift 
with a premature stop codon. Three patients (P6, P8 and 
P16) harboured somatic mosaicisms: a nonsense mutation, 
a 7bp duplication and a 20bp deletion which result in a 
truncating frameshift mutation. One missense mutation 
was located in the DBD. All novel mutations were predicted 
to be pernicious by all in silico tools.
In four individuals (P5, P6, P8 and P16), 17% of AR-mutated 
gene patients, somatic mosaicism of mutant and wild type 
alleles was detected in DNA derived from blood leukocytes. 
Of the 17 individuals without a defect in the AR, two 
patients were finally diagnosed (and genetically confirmed) 
with 5-alpha reductase deficiency. In the others, diagnosis 
remains unknown. 
The clinical phenotype and follow-up of the genetically 
confirmed patients is shown in Supplemental data 
Table 1. Interestingly, during follow-up, no gender dysphoria, 
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1 4 CAIS Female genitalia, inguinal hernia Inguinal F
Female gender 
identity.
2 5.7 CAIS Female genitalia, inguinal hernia Inguinal F
Lost to follow-
up.
3 CAIS Female genitalia, inguinal hernia Inguinal F
4 6.7 CAIS Female genitalia, inguinal hernia Inguinal
F Female gender identity.
5 1.7 PAIS Penoscrotal hypospadias Scrotal 9 M
Pubertal onset 
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including those PAIS patients assigned male or female sex, 
were observed. Unfortunately, in toddler patients, gender 
identity could not be evaluated. According to previous 
reports, very low frequency of gonadal tumors was found. 
Only in P17 was a Sertoli cell tumor detected (8).
Discussion
We describe a series of unrelated patients affected by 
different degrees of AIS. AR gene mutations are the main 
cause of 46,XY DSD. To date, the AR gene mutations 
database (http://www.mcgill.ca/androgendb/) has reported 
more than 800 different AR mutations from patients with 
AIS. 
In all CAIS cases, AR mutations responsible for the 
phenotype were identified. However, similar to other 
cohorts, in PAIS phenotype cases, AR mutations were 
identified in only 38%. Overall, in our series of 41 index 
patients, the AR gene proved to be abnormal in 58.5%, 
confirming the diagnosis. Similarly, Boehmer et al (9) 
and Audi et al (2) report a frequency of detection of 44-
65% which is in line with our results. In contrast de Silva 
et al (10) and Akcay et al (11) describe cohorts with 15-
18% of genetically confirmed AIS. In these studies, the 
significantly lower percentage of AR mutation detection 
could be due to the presence of overlaps in the clinical 
presentation of the patients, such as 5-α reductase 
deficiency or the fact that patients with a T biosynthetic 
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CA: chronologycal age, EMS: external masculinization score (39), CAIS: complete androgen insensitivity syndrome, PAIS: partial androgen insensitivity 
syndrome, F: female, M: male, NA: not available, BMT: bone marrow transplant, T: testosterone, AMH: anti-Müllerian hormone.
Male reference gonadotropin levels (MU/mL). 0-3 months: follicle-stimulating hormone (FSH): 2.43±1.67, luteinising hormone (LH): 2.52±1.74; 3-12 
months: FSH: 1.35±0.81, LH: 1.21±1.65; 12-24 months: FSH: 0.90±0.59, LH: 0.15±0.17; >24 months: FSH: 1.10±0.82, LH: 0.13±0.32; 9-12 years: FSH: 
2.26±0.96 (MU/mL), LH: 0.78±0.99.
Male reference testosterone levels (ng/mL): 1-5 months <0.05-1.77; 6-11 months ≤0.07; 1-5 years ≤0.25; 6-9 years ≤0.30; 10-11 years 0.05-0.50; 12-14 years 
0.10-5.72; 15-17 years 2.20-8.00.
Male reference AMH levels (pmol/L): 0-14 days: 250-1000; 15 days-3 years 400-2400; >3 years prepubertal Tanner 1 300-1400; >3 years pubertal Tanner 2 70-
1000; >3 years pubertal Tanner 3 30-400; >3 years pubertal Tanner 4/5 30-180.
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defect were also included. Therefore, it has been proposed 
that even though AR is essential for virilization, other 
components of the AR complex and signaling network 
are required for complete masculinization. It has been 
suggested that in non-detected cases androgen resistance 
might be secondary to mutations in the 5’UTR, or other 
regulatory regions. Moreover, several necessary AR 
cofactor(s) should also be taken into consideration. Several 
cofactors, such as coactivators steroid receptor coactivator 
1 (SRC1), transcriptional mediators/intermediary factor 
2, SRC3 and corepressors nuclear receptor-interacting 
protein 1, nuclear receptor subfamily 0 group B member 
1, are actively involved in the regulation of AR-mediated 
transcription, and might play an important role in AIS 
etiopathogenesis (12,13,14,15). Interestingly, in order to 
confirm androgen resistance, Hornig et al (16) developed a 
DHT-dependent transcriptional induction of the androgen-
regulated APOD (apolipoprotein D) gene in cultured genital 
fibroblasts (APOD-assay). However, the usefulness of this 
APOD assay needs to be confirmed in a large cohort.
Mutations in the AR gene are distributed throughout the 
sequence with a preponderance (70.8%) located in the LBD 
(17). In our cohort, nine novel AR mutations were found, 
expanding the mutational spectrum of 46, XY DSD. In three 
of these novel mutations, located in the LBD, a truncated, 
significantly reducedor inactive protein was predicted due 
to a premature stop codon, secondary to gene deletion 
(P15), gene duplication (P8) or nonsense mutation (P6). The 
p.Phe726Cys missense mutation located in the LBD was 
also detected. Interestingly the study of Quigley et al (18) 
demonstrated by functional assays that a missense mutation 
in the same position (p.Phe726Leu),caused the disruption 
of the N/C terminal interaction of the mutated protein. 
Hence it might be reasonable to suppose that the novel 
missense mutation found in our cohort might also affect the 
transactivation activity of the AR, impairing the binding of 
the ligand to its LBD. The remaining novel mutations, two 
gene deletions (P1 and P16) located in the NTD domain, 
result in a truncated protein due to a premature stop codon.
A lack of correlation between genotype and clinical 
phenotype has previously been reported (19). Interestingly, 
in siblings of family 12, harbouring p.Asp691del mutation, 
a clinical variability was evident. A CAIS phenotype was 
observed in one case, while in the other a PAIS phenotype 
was observed. Petroli et al’s (20) study showed, in N/C 
terminal interaction assays, different profiles of the mutant 
AR protein in response to DHT stimulation, explaining the 
phenotypic diversity observed in PAIS cases. 
Somatic mosaicism has been reported. Interestingly, even 
though the patients carried severe AR mutations, PAIS 
clinical phenotype was reported. In these affected patients 
the de novo mutation occurred after the zygote stage and 
probably very early, during the first few cell divisions. Thus, 
different proportions of cells containing mutant or wild-type 
protein are present in various tissues of the same individual 
explaining the mild phenotype. Similarly, in four patients 
of our cohort (P5, P6, P8 and P16) a severe mutation 
was detected but presenting with a PAIS phenotype. It is 
noteworthy that detection of somatic mosaicism in AR 
has a great impact for patients with AIS because further 
virilization is possible after birth and this is an important 
consideration for genetic counseling (21).
No gender dysphoria was observed in our cohort, even 
though systematic assessment was not available in all cases.
In contrast to previous reports, in this cohort, AMH serum 
concentrations during the neonatal period were within the 
normal male reference range in the only two PAIS cases 
in whom it was assessed (22,23). AMH gene expression 
in Sertoli cells is inhibited via the AR receptor pathway 
(24). The lack of AR expression in Sertoli cells during mini 
puberty could explain our findings, suggesting that other as 
yet unidentified factors might be involved in the regulation 
of AMH synthesis (25). 
In agreement with previous reports, normal gonadotropin 
levels were the most frequent finding (26). 
Study Limitations
Even though all in silico tools predicted the novel mutations 
to be damaging for protein structure and function, functional 
assays should be performed to confirm pathogenicity.
Conclusion
In summary, we report a series of 41 46,XY DSD index 
patients in whom AR was the candidate gene. Molecular 
diagnosis is useful for genetic counseling of the families. 
However, similar to other series, the percentage of suspected 
casesin whom an AR mutation was found wasonly around 
60%.
Emerging technological advances might contribute to an 
increase in the accuracy of determining the etiology in 
suspected AIS cases. 
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